OHE Lunchtime Seminar with NHS Improvement Economics Team Members Sarah Karlsberg, Steven Paling and Júlia Esquerré. The seminar will present evidence on where NHS trusts can take practical steps to reduce cancer waiting times. The project won the 2018 John Hoy Memorial Award for the best piece of economic analysis produced by government economists.
The latest publication from Professor Graham Cookson in Public Organization Review finds that waiting time targets adopted in the English NHS as part of the ‘targets and terror’ performance management regime did indeed reduce key waiting time measures, but at the expense of other quality metrics such as hospital readmission rates i.e. the policy was output distorting.
OHE Lunchtime Seminar with Dr. Aslam Anis, The University of British Columbia. The seminar will discuss the impact of the pan-Canadian Pharmaceutical Alliance “tiered pricing” framework (a flexible 'price-cap' regulation) on generic entry, the resulting drug expenditure levels from a drug plans’ perspective and the implications of price-capping policies on drug shortages.
This is OHE’s report to the Charity Commission for England and Wales for the year 2017, OHE’s first since becoming a registered charity in December 2016. It demonstrates some of the ways in which OHE has met its charitable objects: namely, to advance the education of the public in general/health care payers/policy makers on the subject of health economics and health care policy.
This OHE Briefing outlines the NHS ownership debate through the lens of economics. The aim of the Briefing is to improve understanding of how economics can or cannot help to resolve the question of whether the private ownership of health care provision is good or bad. The economics literature that informs this overview includes: the theory of the organisation of production; theories of behaviour and motivation and the role of incentives and payments in influencing decisions.
OHE Lunchtime Seminar with Nicholas Timmins on ‘Is hypothecation the way to raise the money for the “multi-year” funding settlement that the NHS has been promised?’ To be held on 25th July 2018 from 12 p.m. to 2 p.m.
The notion that the price of a medicine should be linked in some way to value it generates for patients and the health system is generally accepted. Yet, how can this be achieved, when increasingly medicines are being developed that derive patient benefit across many different indications? Indication-based pricing (IBP) has been proposed as a way to tackle this issue, permitting price to vary according to indication and – critically – according to value.